Quality of ADR reporting evaluated for remdesivir trials of COVID-19
Open Access
- 24 October 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Reactions Weekly
- Vol. 1827 (1), 10
- https://doi.org/10.1007/s40278-020-84767-2
Abstract
No abstract availableKeywords
This publication has 1 reference indexed in Scilit:
- Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19European Journal of Clinical Pharmacology, 2020